Physician profile
Augusto Banayat
NPI 1831727700
$6,142.09
in general payments reported to CMS, 2019-2025
30 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $858 · 2022: $2,982 · 2023: $2,084 · 2024: $34.40 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.92 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $867.04 | 2021-2023 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $607.03 | 2021-2025 | |
| Horizon Therapeutics Plc | $516.73 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $510.31 | 2021-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.35 | 2021-2023 | Ofev |
| Abbvie INC. | $467.18 | 2021-2024 | |
| Janssen Biotech, INC. | $419.66 | 2021-2023 | Simponi Aria, Tremfya |
| Pfizer INC. | $362.84 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $354.64 | 2021-2025 | Lupkynis |
| Ucb, INC. | $265.83 | 2021-2023 | Cimzia |
| Lilly USA, LLC | $233.27 | 2021-2022 | |
| Glaxosmithkline, LLC. | $162.72 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $157.02 | 2022-2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $114.89 | 2022-2023 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $93.02 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $89.70 | 2022-2023 | Purified Cortrophin Gel |
| Bioventus LLC | $63.48 | 2021-2022 | |
| Csl Behring | $57.97 | 2022 | |
| Lundbeck LLC | $46.83 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.39 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $38.53 | 2021 | |
| Biocryst US Sales Co., LLC | $30.45 | 2022 | |
| Hospira, INC. | $25.88 | 2023 | |
| Echosens North America, INC. | $21.93 | 2025 | Fibroscan |
| Pacira Therapeutics, INC. | $19.06 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.05 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.75 | 2023 | Amvuttra |
| Hikma Pharmaceuticals USA | $17.50 | 2023 | Mitigare |
| Novo Nordisk INC | $16.91 | 2023 | Wegovy, Saxenda |
| Eisai INC. | $16.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusto Banayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.